Home / Cancer
Cancer
| 2 min read
NEW YORK—Callisto Pharmaceuticals, a developer of new drug treatments for cancer, biodefence and other health threats, is licensing a new class of compounds called degrasyns from the University of Texas M. D. Anderson Cancer Center for development as cancer drugs. The novel anticancer activity of these analogs is connected to their ability to selectively degrade key proteins involved in tumor cell proliferation and survival, including C-MYC, BCR-ABL and JAK2, which are all important targets for a wide range of tumors.
| 2 min read
AURORA, Colo.—Vitro Diagnostics and PhosphoSolutions, both based here, have announced a research collaboration to characterize intracellular signaling mechanisms involved with regulation of stem cell growth and differentiation.
| 3 min read
MONROVIA, Calif.—With an eye to reducing adverse events, biotherapeutics company Xencor announced it signed a non-exclusive licensing deal with Eli Lilly & Co. for Xencor’s ImmunoFilter technology. Financial terms were not disclosed, but the multi-year deal will see the pharma giant gain access to immunogenicity data and software in exchange for annual fees.
| 3 min read
NEW YORK– In a move to separate disparate business activities, Medis Technologies is spinning off its CellScan work into a new entity called Cell Kinetics Ltd. Cell Kinetics will commercialize equipment for monitoring living cells in combination with chemotherapeutic drugs, and Medis will continue developing fuel cells.
| 2 min read
As you no doubt will have read and heard many times, the world suffered a great loss recently when long-time stem cell advocate Dana Reeve, wife of Christopher Reeve, succumbed to lung cancer.
| 2 min read
Cyclacel Group and Seattle-based Xcyte Therapies announced recently the signing of a definitive agreement to merge the two companies into a publicly-traded international biopharmaceutical company called Cyclacel Pharmaceuticals. The deal largely revolves around the acquisition by Xcyte of all capital stock of Cyclacel Ltd., a wholly-owned subsidiary of Cyclacel Group.
| 2 min read
In January, PerkinElmer Inc. (PKI) announced the appointment of Dr. Karl Hecker as director of R&D for its Boston-based Center of Excellence. Hecker comes to PKI from Invitrogen and brings over 20 years of scientific experience in chemistry and biochemistry applications. Executive Editor Randall C Willis recently spoke with Hecker about his new role at PKI and the industry in general.
| 2 min read
More than 900 new medicines are in development to treat the diseases of aging, according to a report released late last year by the Pharmaceutical Research and Manufacturers of America (PhRMA).
| 2 min read
SuperGen Inc. has entered into a definitive agreement to acquire Montigen Pharmaceuticals Inc., a privately held oncology-focused drug discovery and development company based in Salt Lake City.
| 2 min read
| 3 min read
With an eye toward creating the first comprehensive genetic map of cancer, the National Cancer Institute (NCI) and National Human Genome Research Institute (NHGRI) have launched a pilot effort to study the feasibility of a large-scale sequencing project. If successful, The Cancer Genome Atlas (TCGA) will serve as a basis for a better understanding of the genomic changes and molecular mechanisms of cancer.
